Global Lung Cancer Academy
Sharing Best Practices to Optimize Patient Care in Latin America and Canada
Overview
In recent years, progress in screening of high-risk populations, identification of actionable molecular targets, and immunotherapy have rapidly transformed the treatment paradigm for patients with lung cancer. Aptitude Health developed the Global Lung Cancer Academy to help physicians bridge the gap between innovation and implementation for patient care.
Date and Location
October 21 and 24, 2022; Virtual Meeting
Co-chairs
Corey J. Langer, MD, FACP
University of Pennsylvania Perelman School of Medicine, USA
Carlos H. Barrios, MD
Oncology Research Center at Hospital São Lucas, PUCRS, Brazil
Faculty
Narjust Florez (Duma), MD
Dana-Farber Cancer Institute/Harvard Cancer Center
Barbara Melosky, MD, FRCP
University of British Columbia Vancouver, Canada
Edgardo S. Santos, MD
GenesisCare Hematology/Oncology, USA
Anne S. Tsao, MD, MBA
University of Texas MD Anderson Cancer Center, USA
Ignacio I. Wistuba, MD
MD Anderson Cancer Center, USA
William William, MD
BP, A Beneficência Portuguesa de São Paulo, Brazil
|
Agenda |
This 2-day interactive virtual meeting with global experts will focus on the management of patients with lung cancer in Latin America and Canada. Day 1: Follow presentations and engage with the faculty in case-based panel discussions on optimal treatment and patient access, and regional challenges across Latin America and Canada Day 2: Join presentations on region-specific management and treatment strategies for early-stage and metastatic NSCLC in Latin America and attend patient case-based panel discussions exemplifying these strategies |
Day 1 – Plenary Sessions
Friday, October 21, 2022 from 4.00 PM – 8.00 PM EDT (GMT –4)
| Time | Topic | Speaker |
| 4.00 PM – 4.10 PM |
Welcome and Meeting Overview | Corey Langer |
| 4.10 PM – 4.40 PM |
Recent Developments in NSCLC – What Is New in Research and Management? • Overview of recently presented data in NSCLC |
Corey Langer |
| 4.40 PM – 5.00 PM |
Biomarker and Mutational Testing for NSCLC – What, Where, and When? • NSCLC heterogeneity, overview of current and emerging biomarkers and comutations, and best practices and guidelines for testing at diagnosis and during treatment of NSCLC |
Ignacio Wistuba |
| 5.00 PM – 5.20 PM |
Neoadjuvant Therapy for NSCLC – Is It Ready for Prime Time? • Current state of neoadjuvant therapy in resectable vs unresectable NSCLC |
Anne Tsao |
| 5.20 PM – 5.50 PM |
Debate: Adjuvant or Neoadjuvant Therapy for NSCLC? • Neoadjuvant therapy • Adjuvant therapy • Discussion and voting |
Moderator: Corey Langer Anne Tsao Narjust Florez All faculty |
| 5.50 PM – 6.00 PM |
Break | |
| 6.00 PM – 6.20 PM |
Locally Advanced, Unresectable NSCLC – What Are the Options? • Current standard practices and ongoing studies |
Edgardo S. Santos |
| 6.20 PM – 6.40 PM |
Targeted Therapies for NSCLC • Summary of targeted therapies for different NSCLC genotypes |
Barbara Melosky |
| 6.40 PM – 7.00 PM |
Immunotherapy Approaches for Advanced NSCLC • Predictive biomarkers, monotherapy vs combination therapy strategies, mechanism of resistance, and rechallenge |
Edgardo S. Santos |
| 7.00 PM – 7.20 PM |
De Novo – or at Relapse – Oligometastatic NSCLC: Management of Local and Systemic Disease • Work-up of first recurrence vs de novo oligometastatic NSCLC including sites of involvement (isolated vs systemic recurrence) |
Narjust Florez |
| 7.20 PM – 7.50 PM |
Tumor Board Discussion • Case 1: Resectable Stage III NSCLC • Case 2: Resectable Stage III NSCLC • Discussion and Q&A |
Moderator: Corey Langer Vinícius Lorandi Barbara Melosky All faculty |
| 7.50 PM – 8.00 PM |
Session Close | Corey Langer |
Day 2: Virtual Plenary Session – Limited Access Sessions
Monday, 24 October 2022 from 4.00 PM – 7.00 PM EDT (GMT –4)
| Time | Topic | Speaker |
| 4.00 PM – 4.10 PM |
Session Open | Corey Langer and Carlos Barrios |
| 4.10 PM – 4.40 PM |
Interactive Discussion: Regional Challenges in NSCLC Management • Interactive discussion and Q&A (15 min) |
Moderator: Carlos Barrios All faculty |
| 4.40 PM – 5.00 PM |
Current Diagnostic Options and Initial Management of Early-Stage NSCLC in Latin America • Overview of currently available diagnostic methods and treatment options for early-stage NSCLC (resectable vs unresectable) |
William William |
| 5.00 PM – 5.20 PM |
Current Treatment Options for Metastatic NSCLC in Latin America • Overview of currently available treatment options for metastatic NSCLC |
Carlos Barrios |
| 5.20 PM – 5.50 PM |
Tumor Board Discussion • Case 1: EGFR+ metastatic NSCLC • Case 2: HER2+ metastatic NSCLC • Discussion and Q&A |
Moderator: Carlos Barrios Caio Abner Leite Alvaro Guimaraes Paula All faculty |
| 5.50 PM – 6.00 PM |
Break | |
| 6.00 PM – 6.20 PM |
Monitoring and Managing Immunotherapy-Related AEs • Optimal monitoring and managing of the most common AEs associated with immunotherapy |
Edgardo S. Santos |
| 6.20 PM – 6.50 PM |
Tumor Board Discussion • Patient case (10 min) • Discussion and Q&A (20 min) |
Moderator: Corey Langer Barbara Melosky |
| 6.50 PM – 7.00 PM |
Session Close | Carlos Barrios |
